Individual Collapses During Trump's Drug Pricing Announcement at the White House

Post by : Raina Nasser

Washington — Tension momentarily gripped a White House event led by President Donald Trump on Thursday, as an individual fainted behind him during a significant announcement regarding the reduction of weight-loss drug prices. The gathering paused for nearly an hour as medical personnel assured the individual’s safety.

The incident transpired while Eli Lilly's CEO, David Ricks, was discussing a new agreement with the U.S. government aimed at lowering prices for widely used weight-loss medications. The collapsed individual, recognized as a representative from a pharmaceutical company, was positioned among other executives and Trump administration officials behind the presidential desk.

“Are you alright?” Ricks was heard inquiring as bystanders aided the individual to the floor. Attendees had reportedly been standing for about 30 minutes amidst the warm atmosphere of the Oval Office before the mishap occurred.

Trump swiftly rose from behind his desk as medical staff provided assistance. The individual received medical attention from Mehmet Oz, Trump’s administrator for the Centers for Medicare and Medicaid Services, who later reassured attendees that he was in good health.

“He felt a bit light-headed… You saw that he went down. He’s perfectly fine,” Trump remarked after the event resumed. “They quickly took care of him, and he’s under doctors’ care now.”

In a later briefing, David Ricks elucidated that the individual, named Gordon, was a guest of Eli Lilly.

“He momentarily lost consciousness — it’s warm, and standing for long periods in the Oval Office isn’t easy,” Ricks stated. “The White House medical team was exemplary. He’s doing well; there’s nothing to worry about.”

Trump Proclaims Weight-Loss Drug Pricing Initiative

During the event, President Trump unveiled substantial price agreements with pharmaceutical leaders Eli Lilly and Novo Nordisk, aiming to enhance the affordability of popular GLP-1 weight-loss drugs, including Zepbound and Wegovy, for American consumers.

“These companies have consented to provide their most utilized weight-loss medications at considerable discounts,” Trump announced. “This initiative will serve to alleviate the financial burden on Americans seeking access to these transformative treatments.”

GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, have seen a rise in popularity due to their effective weight-loss capabilities; however, their steep prices, often surpassing $1,000 monthly, have raised significant affordability issues within the United States.

This agreement is part of Trump’s administration’s effort to ensure lower prices while mitigating tariff concerns for the pharmaceutical industry.